Sanofi gets first ever approval within Niemann-Pick as Japan green-lights drug

As the first country in the world, Japan has approved a treatment, Sanofi-developed Xenpozyme, for Niemann-Pick disease type A, also known as acid sphingomyelinase deficiency (ASMD).

Photo: Benoit Tessier/Reuters/Ritzau Scanpix

Sanofi is the first and only company in the world to receive an approval for a drug targeting the disease acid sphingomyelinase deficiency (ASMD), Sanofi reports in a press release.

This also makes Japan the first country in the world to approve a drug in this indication, as it was the Japanese health authority that granted Sanofi the approval for Xenpozyme (olipudase alfa) as a treatment for adults and children with non-central nervous system manifestations of ASMD.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs